Literature DB >> 10379858

Markedly elevated levels of vascular endothelial growth factor in malignant ascites.

B K Zebrowski1, W Liu, K Ramirez, Y Akagi, G B Mills, L M Ellis.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that also has the ability to increase vascular permeability. Malignant ascites has significant morbidity, but the mechanism of its development is unknown. Because of the permeability-inducing properties of VEGF, we hypothesized that malignant ascites formation is associated with high levels of VEGF. The purpose of our study was to determine the role of VEGF in malignant ascites formation.
METHODS: Ascites from 25 patients with gastric (n = 6), colon (n = 7), or ovarian (n = 12) cancers was collected by paracentesis or surgery. VEGF protein levels were determined by enzyme-linked immunosorbent assay. The effect of ascites on endothelial cell permeability was assessed by evaluating propidium iodide uptake by human umbilical vein endothelial cells (HUVECs) exposed to ascites. Neutralizing antibodies to VEGF added to ascites were used to determine the causal effect of VEGF in permeability induction.
RESULTS: VEGF protein levels were markedly increased in malignant ascites compared with levels in nonmalignant cirrhotic ascites (controls). VEGF protein levels in ovarian, gastric, and colon cancer ascites were found to be increased 45, 23, and 12 times, respectively, compared with levels in cirrhotic ascites. Malignant ascites from patients with colon and gastric cancer caused an increase in permeability in HUVECs in all cases. Neutralizing VEGF activity in colon cancer ascites decreased in-vitro HUVEC permeability in three of four cases.
CONCLUSIONS: VEGF protein levels are markedly elevated in malignant ascites. VEGF may play a role in malignant ascites formation by increasing endothelial cell permeability.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10379858     DOI: 10.1007/s10434-999-0373-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  69 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Authors:  Suma L Sangisetty; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2012-04-27

Review 3.  Aiming to immune elimination of ovarian cancer stem cells.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Carl G Figdor; Ruurd Torensma
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

Review 4.  Role of the cytoskeleton in formation and maintenance of angiogenic sprouts.

Authors:  Kayla J Bayless; Greg A Johnson
Journal:  J Vasc Res       Date:  2011-04-04       Impact factor: 1.934

5.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.

Authors:  Tao Yin; Guoping Wang; Sisi He; Guobo Shen; Chao Su; Yan Zhang; Xiawei Wei; Tinghong Ye; Ling Li; Shengyong Yang; Dan Li; Fuchun Guo; Zeming Mo; Yang Wan; Ping Ai; Xiaojuan Zhou; Yantong Liu; Yongsheng Wang; Yuquan Wei
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

Review 6.  Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer.

Authors:  Muhammad Wasif Saif; Valerie Relias; Kostas Syrigos; Krishna S Gunturu
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Prognostic and predictive value of serum vascular endothelial growth factor (VEGF) in squamous cell carcinoma of the head and neck.

Authors:  Bijan Khademi; Mehdi Soleimanpour; Abbas Ghaderi; Mohammad Mohammadianpanah
Journal:  Oral Maxillofac Surg       Date:  2013-03-03

Review 8.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

Review 9.  Evaluation and treatment of malignant ascites secondary to gastric cancer.

Authors:  Hiromichi Maeda; Michiya Kobayashi; Junichi Sakamoto
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations.

Authors:  Ning Miao; James F Pingpank; H Richard Alexander; Richard Royal; Seth M Steinberg; Martha M Quezado; Tatiana Beresnev; Zenaide M N Quezado
Journal:  Ann Surg Oncol       Date:  2008-12-03       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.